

CBDMT® - MARKET AND BUSINESS INTELLIGENCE

Pharmaceutical Industry

In a year of transition, global pharmaceutical sales are expecting to grow 5-6% to over 735 USD billion in 2008 (including generics), compared with 6-7 % in 2007, driven by the declining costs of drug treatment in major therapy areas, increased uncertainty over safety, pricing and market access, and intellectual property issues. There will also be a shift in growth from the top seven markets to emerging markets, and from primary care-driven to specialty care-driven drugs.

Fastest growing treatment categories :

- vaccines with over 15-18% per annum to 2011, driven by strong HPV vaccines (Cervarix, Gardasil), paediatric vaccines (Rotarix),
- HIV with an expected growth of 12-13% per annum driven by high prevalence, success of triple combination therapies and new launches,
- Neurodegeneration with a growth of 12-15% per annum driven by interferons, Copaxone and Tysabri.

CBDM.T® last focus:



Drug discovery

BIOMARKERS	BIOINFORMATICS	LEAD OPTIMIZATION
EMERGING TECHNOLOGIES		ADAPTIVE TRIALS
DRUG DEVELOPMENT IN CHINA		NANOTECHNOLOGY



Strategy

LICENSING	OUTSOURCING	ALLIANCES	LIFECYCLE
BRANDING	CONTRACT MANUFACTURING		R&D PRODUCTIVITY
CRO	GROWTH OPPORTUNITIES IN BRIC		



Markets

VACCINES	CNS	EMERGING MARKETS	TECHNOLOGY
CARDIOVASCULAR	HIV/AIDS	PRICING	ANTI-INFECTIVES
ALZHEIMER	GASTROINTESTINAL	DERMATOLOGY	CANCER



Other

MARKET VALUATION	NPV MODELS	PRODUCT PIPELINE ANALYSIS
INFORMATION AND COMMUNICATION TECHNOLOGIES IN HEALTHCARE		

CBDM.T® FRANCE - 88-90 Rue de la Mare - Fr- 75020 PARIS- FRANCE Tel/Fax: +33 1 4474 7957

CBDM.T® ISRAEL - POBox 6235 -NETANYA 42490 - ISRAEL Tel: +972 52 3316190

CBDM.T® SWITZERLAND - 6 route de Meyrin -CH 1202 GENEVA- Switzerland

contact@cbdmt.com

See also www.cbdmt.com